oxidopamine has been researched along with Anxiety Neuroses in 5 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Anxiety in Parkinson's disease may represent a physiological reaction to the development of other symptoms during disease progression." | 1.51 | Anxiety-like behavior induced by 6-OHDA animal model of Parkinson's disease may be related to a dysregulation of neurotransmitter systems in brain areas related to anxiety. ( Bassani, TB; da Cunha, C; de O Guaita, G; Santiago, RM; Vieira, JCF; Vital, MABF; Zanoveli, JM, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vieira, JCF | 1 |
| Bassani, TB | 1 |
| Santiago, RM | 1 |
| de O Guaita, G | 1 |
| Zanoveli, JM | 1 |
| da Cunha, C | 1 |
| Vital, MABF | 1 |
| Sun, YN | 1 |
| Wang, T | 2 |
| Wang, Y | 2 |
| Han, LN | 1 |
| Li, LB | 1 |
| Zhang, YM | 1 |
| Liu, J | 2 |
| Faggiani, E | 1 |
| Delaville, C | 1 |
| Benazzouz, A | 1 |
| O'Connor, KA | 1 |
| Feustel, PJ | 1 |
| Ramirez-Zamora, A | 1 |
| Molho, E | 1 |
| Pilitsis, JG | 1 |
| Shin, DS | 1 |
| Chen, L | 1 |
| Ali, U | 1 |
| Gui, ZH | 1 |
| Hou, C | 1 |
| Fan, LL | 1 |
5 other studies available for oxidopamine and Anxiety Neuroses
| Article | Year |
|---|---|
Anxiety-like behavior induced by 6-OHDA animal model of Parkinson's disease may be related to a dysregulation of neurotransmitter systems in brain areas related to anxiety.
Topics: Adrenergic Agents; Amygdala; Animals; Anxiety; Anxiety Disorders; Behavior, Animal; Brain; Corpus St | 2019 |
Activation of 5-HT₁A receptors in the medial subdivision of the central nucleus of the amygdala produces anxiolytic effects in a rat model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Animals; Anti-Anxiety Agents; Anxiety Dis | 2015 |
The combined depletion of monoamines alters the effectiveness of subthalamic deep brain stimulation.
Topics: Animals; Anxiety Disorders; Benzylamines; Biogenic Monoamines; Catalepsy; Corpus Striatum; Deep Brai | 2015 |
Investigation of diazepam efficacy on anxiety-like behavior in hemiparkinsonian rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Diazepam; Exploratory Behavior; Functional Laterali | 2016 |
Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist produces anxiolytic-like effects and reverses abnormal firing activity of projection neurons in the basolateral nucleus of the amygdala in rats with bilateral 6-OHDA lesions.
Topics: Amygdala; Animals; Anxiety Disorders; Disease Models, Animal; Excitatory Amino Acid Antagonists; Mal | 2011 |